REVIEW ARTICLE

Emerging Innovations in Stimuli-Responsive Drug Carriers for Targeted Therapeutic Delivery

Nadeem Siddiqui[1], Anirudh Vivin Sabbi[1], Manjusha Gunupudi[1], Kochera Rachel[1], Athoti Revanth[1], Jahnavi Devi Damisetty[1], Likhith Sai Charan Bonda[1], Sravya Amrutha Garaga[1], B. Ramya Sree[2]

[1]Department of Biotechnology, Koneru Lakshmaiah Education Foundation, Guntur, Andhra Pradesh, India, [2]Department of Biotechnology, GITAM School of Technology, GITAM deemed to be University, Visakhapatnam, Andhra Pradesh, India

Abstract

Targeted drug delivery has revolutionized modern medicine by enabling the precise delivery of therapeutics to specific sites while minimizing systemic side effects. This comprehensive review explores recent advancements in targeted drug delivery systems, focusing on nanotechnology-based approaches, stimuli-responsive carriers, and innovative targeting strategies. Nanoparticles, including liposomes, polymeric nanoparticles, and inorganic nanoparticles, offer enhanced drug solubility and targeted delivery to specific tissues or cells. Stimuli-responsive drug carriers respond to environmental cues, allowing for controlled drug release. Targeting strategies employ ligands to bind to receptors on target cells, enabling precise delivery of therapeutics. Applications span various diseases, including cancer, neurological disorders, infectious diseases, and chronic conditions. Despite challenges such as biocompatibility and regulatory considerations, targeted drug delivery holds promise for personalized medicine, improving therapeutic efficacy, and patient outcomes.

Key words: Nanoparticles, nanotechnology, stimuli-responsive carriers, targeted drug delivery, targeting strategies

INTRODUCTION

Targeted drug delivery has emerged as a transformative approach in modern medicine, offering the potential to revolutionize the efficacy and safety of therapeutic interventions.[1] Traditional drug delivery methods often suffer from non-specific distribution, resulting in systemic toxicity and suboptimal therapeutic outcomes.[2] In contrast, targeted drug delivery systems aim to deliver therapeutics specifically to the site of action, thereby enhancing efficacy while minimizing off-target effects.[3] This comprehensive review aims to provide an in-depth exploration of recent advancements in targeted drug delivery, encompassing a wide array of technologies and strategies.[4] The review will delve into nanotechnology-based approaches, stimuli-responsive drug carriers, innovative targeting strategies, and their applications across various disease contexts.[5] Nanotechnology has played a pivotal role in advancing targeted drug delivery, with nanoparticles serving as versatile platforms for drug encapsulation and delivery.[6,7] These nanocarriers offer several advantages, including improved drug solubility, prolonged circulation time, and the ability to target specific tissues or cells. By encapsulating therapeutic agents within nanoparticles, researchers can achieve controlled release kinetics and enhance the therapeutic index of drugs.[8] Moreover, stimuli-responsive drug carriers represent a cutting-edge approach in targeted drug delivery, enabling on-demand drug release in response to specific triggers present in the disease microenvironment. These carriers can be designed to respond to various stimuli, such as pH, temperature, light, or enzymatic activity, providing spatiotemporal control over drug release.[9] In addition to carrier design, targeting strategies have also evolved

Address for correspondence:
Dr. Nadeem Siddiqui, Department of Biotechnology, Koneru Lakshmaiah Education Foundation, Guntur, Andhra Pradesh, India.
E-mail: siddiqui@kluniversity.in

Received: 20-05-2024
Revised: 21-08-2024
Accepted: 06-09-2024

significantly, with the development of ligand-mediated targeting approaches that enable precise delivery of therapeutics to diseased cells or tissues.[10] Active targeting strategies leverage ligands, such as antibodies, peptides, or aptamers, to selectively bind to receptors or antigens overexpressed on target cells, enhancing drug accumulation and therapeutic efficacy.[11] Overall, this review will provide a comprehensive overview of the latest advancements in targeted drug delivery, highlighting their potential to transform the landscape of modern medicine and improve patient outcomes across diverse disease contexts.[12]

NANOTECHNOLOGY-BASED DRUG DELIVERY SYSTEMS

Nanoparticles, including liposomes, polymeric nanoparticles, dendrimers, and inorganic nanoparticles, have emerged as versatile platforms for targeted drug delivery. These nanocarriers offer several advantages, such as enhanced drug solubility, prolonged circulation time, and targeted delivery to specific tissues or cells.[13,14] Recent advancements in nanoparticle engineering have led to improved drug loading, stability, and targeting capabilities. Case studies demonstrate the clinical translation of nanoparticle-based drug delivery systems, highlighting their potential to enhance therapeutic efficacy and minimize side effects.[15] It utilizes nano-sized particles to precisely target and deliver medications to specific cells or tissues within the body. These systems offer numerous advantages, including improved drug solubility, prolonged circulation time, and enhanced bioavailability. By encapsulating drugs within nanoparticles, researchers can bypass biological barriers, reduce side effects, and achieve controlled release kinetics.[16] In addition, surface modifications allow for targeted delivery to diseased sites, minimizing systemic toxicity. Nanotechnology-based drug delivery holds immense potential in revolutionizing healthcare by offering personalized and efficient therapeutic interventions for various diseases, ranging from cancer to neurological disorders, ushering in a new era of precision medicine [Figure 1].

STIMULI-RESPONSIVE DRUG CARRIERS

Stimuli-responsive drug delivery systems have gained significant attention due to their ability to release therapeutic agents in response to specific stimuli, such as pH, temperature, light, magnetic field, or enzymatic triggers.[18] These carriers are designed to respond to the unique microenvironment of the target site, allowing for controlled drug release and activation. Applications of stimuli-responsive carriers in targeted therapy include cancer treatment, where localized delivery of chemotherapeutic agents can be achieved through tumor-specific stimuli.[19] Stimuli-responsive drug carriers are innovative vehicles designed to transport therapeutic agents to target sites within the body, offering precise control over drug release. These carriers, often crafted from biocompatible materials, exhibit dynamic behaviors triggered by specific stimuli such as pH, temperature, light, or enzymes found in the body.[20] Upon encountering the designated trigger, they undergo structural changes, leading to controlled drug release. This targeted delivery system minimizes off-target effects, enhances therapeutic efficacy, and reduces side effects.[21] Examples include pH-sensitive polymers that release drugs in acidic environments like tumor tissues, or thermo-responsive liposomes triggered by mild hyperthermia at the site of inflammation. By harnessing the body's internal cues, stimuli-responsive drug carriers offer a promising approach in personalized medicine, allowing tailored treatment strategies for various diseases while minimizing systemic toxicity.[22] Their versatility and adaptability hold significant promise in advancing drug delivery technologies toward safer and more effective therapeutic interventions [Table 1].



Figure 1: Relative distribution of nanomaterials used in drug products that were submitted to the FDA from 2010 to 2015 (Adapted from D'Mello *et al*.)[17]

Table 1: Overview of different types of stimuli-responsive drug carriers

Drug carrier	Stimulus trigger	Application
pH-sensitive polymers	pH changes	Targeted drug delivery to acidic tissues
Light-activated	Light exposure	Spatially controlled drug release
Hydrogels	Enzyme activity	Triggered release in response to enzymes

Table 2: Overview of different targeting strategies in drug delivery

Targeting Strategy	Description	Example
Passive targeting	Exploits physiological characteristics, like leaky vasculature in tumors, for drug accumulation.	Enhanced permeability and retention effect in cancer therapy
Active targeting	Utilizes ligands (e.g., antibodies, peptides) to bind specifically to target cells or receptors.	Antibody-conjugated nanoparticles targeting cancer cells
Stimuli-responsive targeting	Drug carriers respond to specific stimuli (e.g., pH, temperature) triggering drug release.	pH-sensitive polymers releasing drugs in acidic tumor microenvironments

TARGETING STRATEGIES IN DRUG DELIVERY

Targeted drug delivery can be achieved through active or passive targeting approaches. Active targeting involves the use of ligands, such as antibodies, peptides, aptamers, or small molecules, to specifically bind to receptors or antigens on target cells.[23] Passive targeting relies on the enhanced permeability and retention effect, which exploits the leaky vasculature and impaired lymphatic drainage of tumors to accumulate nanoparticles selectively. Cell-specific targeting strategies have been developed for various cell types, including cancer cells, endothelial cells, immune cells, and neurons, enabling precise delivery of therapeutics to diseased tissues or organs.[24] Targeting strategies in drug delivery focus on directing therapeutic agents precisely to the desired sites within the body, enhancing efficacy while minimizing side effects. These strategies include passive targeting, exploiting physiological characteristics, such as leaky vasculature in tumors; active targeting, employing ligands to bind specifically to target cells or receptors; and stimuli-responsive targeting, utilizing triggers such as pH, temperature, or enzymes to release drugs at specific locations.[25] By employing these strategies, drug delivery systems can achieve improved therapeutic outcomes, reducing off-target effects and maximizing the therapeutic index of medications [Table 2].

APPLICATIONS IN DISEASE THERAPY

Targeted drug delivery systems have shown promising applications in the treatment of various diseases, including cancer, neurological disorders, infectious diseases, and chronic conditions. In cancer therapy, targeted delivery of chemotherapy, immunotherapy, and gene therapy have been explored to improve therapeutic outcomes and reduce systemic toxicity.[26] For neurological disorders, targeted drug delivery strategies aim to overcome the blood-brain barrier and deliver therapeutics to neurons and glial cells, offering potential treatments for neurodegenerative diseases and brain tumors. In infectious diseases, site-specific delivery of antimicrobial agents and vaccines can enhance efficacy and minimize off-target effects. In addition, targeted drug delivery to inflamed tissues and organs holds promise for the treatment of chronic inflammatory conditions.[27]

Stimuli-responsive drug carriers have emerged as powerful tools in disease therapy, offering precise control over drug release and targeting. Light-activated drug carriers offer spatially controlled drug release, allowing precise targeting of tumors or infected tissues with minimal damage to healthy cells.[28] In addition to cancer and inflammatory diseases, stimuli-responsive drug carriers hold promise in treating infectious diseases. Hydrogels sensitive to enzyme activity can deliver antimicrobial agents in response to pathogenic enzymes, offering a targeted approach to combat infections. Overall, stimuli-responsive drug carriers represent a versatile platform for disease therapy, facilitating personalized and targeted treatment strategies across a wide range of medical conditions, ultimately improving patient outcomes and quality of life.[29]

CHALLENGES AND FUTURE PERSPECTIVES

Despite the significant progress in targeted drug delivery, several challenges remain to be addressed. Biocompatibility, toxicity, and immunogenicity concerns associated with nanocarriers pose safety considerations for clinical translation.[30] Overcoming biological barriers, such as the blood-brain barrier or tumor microenvironment, remains a significant hurdle for effective targeting and drug delivery. Integration of imaging and diagnostic modalities with targeted drug delivery systems can improve treatment monitoring and patient outcomes.[31] Regulatory considerations and commercialization challenges also need to be addressed to facilitate the translation of targeted drug delivery technologies into clinical practice. Future directions in personalized medicine and precision drug delivery hold promise for tailoring treatments to individual patient characteristics, maximizing therapeutic efficacy, and minimizing adverse effects.[32]

CONCLUSION

Advancements in targeted drug delivery have transformed the landscape of modern medicine, offering precise and efficient delivery of therapeutics to diseased tissues or cells. Nanotechnology-based drug delivery systems, stimuli-responsive carriers, and innovative targeting strategies have

shown promising applications in the treatment of cancer, neurological disorders, infectious diseases, and chronic conditions. Addressing current challenges and exploring future directions in personalized medicine will further accelerate the development and clinical translation of targeted drug delivery technologies, ultimately improving patient outcomes and quality of life. Advancements in targeted drug delivery have revolutionized therapeutic interventions, offering precise and personalized treatment strategies across a spectrum of diseases. These innovations have significantly enhanced drug efficacy while minimizing systemic side effects, thereby improving patient outcomes and quality of life. The integration of passive and active targeting strategies, coupled with stimuli-responsive drug carriers, continues to expand the frontiers of medicine, enabling tailored approaches for individual patients. As research progresses and technologies evolve, the future holds promise for even more sophisticated targeted drug delivery systems, fostering a new era of precision medicine and transformative healthcare solutions.

REFERENCES

1. Zhu C, Liu L, Yang Q, Lv F, Wang. Stimuli-responsive polymeric micelles for anti-cancer drug delivery. Chem Soc Rev 2016;45:7774-89.
2. Shao D, Zheng R, Wang J, Tian X, Zhang J. Stimuli-responsive nanocarriers for therapeutic applications. J Control Release 2017;252:135-47.
3. Lee Y, Lee SH, Shin DW, Lee HJ. Recent progress in stimuli-responsive nanomaterials for biomedical applications. Adv Funct Mater 2018;28:1704395.
4. Koo H, Huh MS, Sun IC, Yin Y, Choi K, Kim K. Stimuli-responsive nanoplatforms for delivery of molecular therapeutics. Nanoscale 2015;7:8966-81.
5. Wang Y, Zhuang X, Li S, Ding J, Chen X. Stimuli-responsive polypeptide nanogels for on-demand drug delivery against cancers. Adv Drug Deliv Rev 2019;144:61-78.
6. Tong R, Hemmati HD, Langer R, Kohane D. Glucose-responsive nanomaterials for smart drug delivery. Chem Soc Rev 2018;47:7801-16.
7. Ji X, Chen Y, Zhao Y, Chen L. Stimuli-responsive metal-organic frameworks for drug delivery. Coord Chem Rev 2019;385:75-96.
8. Liu J, Pang Y, Zhang Z, Yang D, Deng J. Smart stimuli-responsive nanocarriers for controlled anticancer drug delivery. Theranostics 2019;9:3213-32.
9. Ganta S, Devalapally H, Shahiwala A, Amiji M. Stimuli-responsive nanocarriers for drug delivery: Insights into design and applications. Expert Opin Drug Deliv 2014;11:861-79.
10. Chytil P, Etrych T, Šubr V, Ulbrich K. The development of smart polymer nanocarriers for targeted cancer therapy. Chem Soc Rev 2020;49:3640-68.
11. Feng W, Zhou Y, Shen C, Li M, Tian T, Fang Y. Advances in smart mesoporous carbonbased nanocarriers for cancer therapy. Nanoscale 2018;10:22327-36.
12. Wang D, Chen J, Wang S, Wang X, Zhang Y. Stimuli-responsive nanocarriers for the delivery of therapeutic nucleic acids. J Control Release 2018;285:130-44.
13. Zhao Z, Yang W, Ren J, Qu K, Wang J. Advances in stimuli-responsive nanoparticles for anticancer drug delivery. Curr Pharm Des 2017;23:421-35.
14. Kou J, Liu X, Zhang L, Chen C, Wang X. Stimuli-responsive polymeric micelles: A promising nanoplatform for targeted cancer therapy. J Mater Chem B 2020;8:4724-39.
15. Cobo I, Li M, Sumerlin B, Perrier S. Smart polymer nanocontainers for stimuliresponsive delivery. Adv Mater 2015;27:743-8.
16. Zhang H, Zou T, Liu X, Duan Y, Ma F, Zhou L. Smart stimuli-responsive liposomes for drug delivery. Chem Soc Rev 2013;42:140-51.
17. D'Mello R, Anselmo K, Mitragotri P. Trends in FDA drug approvals over the last decade: 2010 to 2015. Drug Discov Today 2016;21:1231-40.
18. Liu GS, Cai X, Gao W, Jiang Y, Zeng M. Stimuli-responsive block copolymer assemblies for cancer therapy. Adv Drug Deliv Rev 2012;64:1447-58.
19. Chen Y, Huang J, Yang L, Yang Q. Smart polymers for drug delivery: Recent advances and challenges. Eur Polym J 2019;112:120-34.
20. Wang H, Zhao T, Zhang W, Wang X. Light-responsive nanomedicines for cancer treatment. Adv Drug Deliv Rev 2019;139:73-89.
21. Cheng R, Meng F, Deng C, Klok HA, Zhong Z. Dual and multi-stimuli responsive polymeric nanoparticles for programmed site-specific drug delivery. Biomaterials 2013;34:3647-57.
22. Liu G, Wang X, Hu J, Zhang G, Liu S. Design of stimuli-responsive nanogels for targeted drug delivery. Theranostics 2013;3:64-75.
23. Yang Y, Wei X, Zhao Z, Wei Z, Du Y. Redox-responsive nanocarriers for drug delivery: From molecular design to therapeutic applications. Adv Drug Deliv Rev 2016;105:228-41.
24. Mai Y, Du R, Xin Y, Liu Z, Li X. Multifunctional mesoporous silica nanoparticles for stimuli-responsive drug delivery. Micropor Mesopor Mater 2016;236:141-52.
25. Lee S, Lee JS, Yang K, Lee DS, Kim JK. Stimuli-responsive lipid-based nanocarriers for anticancer drug delivery. Nanomedicine 2017;12:1415-31.
26. Zhang P, Wu X, Kong L. Smart hollow nanoparticles for anticancer drug delivery. Front Chem 2018;6:402.
27. Zhang J, Wang C, Yang F. Multifunctional and stimuli-responsive magnetic nanocarriers for drug delivery. Nanomedicine 2018;13:1495-510.
28. Nairi V, Caron N, Meunier M. Recent advances in stimuli-responsive nanosystems for cancer therapy. Int J Pharm 2020;576:118961.
29. Yao C, Zhang S, Zhang Y, Zhang W, Li H, Hu B. Enzyme-responsive polymeric micelles for drug delivery. ACS Appl Mater Interfaces 2018;10:30936-46.
30. Chen J, Bai X, Zhang H, Wu P, Zhang Y, Li W.

Smart stimuli-responsive nanogels in applications of drug delivery. Crit Rev Ther Drug Carrier Syst 2017;34:341-80.
31. Tian H, Zhang X, Chandra R, Yang Y, Zhang W, Chen Y. Polymer-drug conjugates: Recent development in clinical cancer therapy. Adv Mater 2014;26:6552-79.
32. Park JH, Kim MJ, Ryu HW, Kim DS, Park SK, Lee HJ. Dual stimuli-responsive polymeric micelles for drug delivery. Nanomedicine 2015;11:987-94.

Source of Support: Nil. **Conflicts of Interest:** None declared.